Compare ARQT & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARQT | FSK |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2020 | 2008 |
| Metric | ARQT | FSK |
|---|---|---|
| Price | $23.32 | $11.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 8 |
| Target Price | ★ $34.00 | $13.19 |
| AVG Volume (30 Days) | 905.0K | ★ 3.1M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 18.82% |
| EPS Growth | ★ 88.79 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $376,072,000.00 | N/A |
| Revenue This Year | $34.85 | N/A |
| Revenue Next Year | $29.39 | N/A |
| P/E Ratio | ★ N/A | $280.75 |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $12.42 | $9.72 |
| 52 Week High | $31.77 | $22.68 |
| Indicator | ARQT | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 61.20 |
| Support Level | $22.56 | $9.85 |
| Resistance Level | $23.46 | $15.19 |
| Average True Range (ATR) | 0.94 | 0.35 |
| MACD | -0.07 | 0.08 |
| Stochastic Oscillator | 36.38 | 96.09 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.